Association between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose

JAMA Internal Medicine

Volumn 179, Issue 6, 2019, Pages 805-811

  Abouk, Rahi ^a   Pacula, Rosalie Liccardo ^b,c   Powell, David ^b  

^a WILLIAM PATERSON UNIVERSITY   (United States)

^b RAND CORPORATION   (United States)

^c NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; METHADONE; NALOXONE; OPIATE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ARTICLE; DRUG FATALITY; DRUG OVERDOSE; HUMAN; LAW; PHARMACIST; PHARMACY (SHOP); PRESCRIPTION; PRIORITY JOURNAL; ADULT; DRUG CONTROL; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE; MALE; MIDDLE AGED; MORTALITY; OPIATE ADDICTION; RISK ASSESSMENT; UNITED STATES;

ADULT; ANALGESICS, OPIOID; DRUG AND NARCOTIC CONTROL; DRUG OVERDOSE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RISK ASSESSMENT; UNITED STATES;

EID: 85065179624     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2019.0272     Document Type: Article

References (28)

1. Hedegaard H, Warner M, Minino AM. Drug Overdose Deaths in the United States, 1999-2016. NCHS Data Brief, no 294. Hyattsville, MD: National Center for Health Statistics; 2017.
2. Humphreys K. Avoiding globalisation of the prescription opioid epidemic. Lancet. 2017; 390 (10093): 437-439. doi: 10.1016/S0140-6736(17)31918-9 28792397
3. Paulozzi LJ. Prescription drug overdoses: a review. J Safety Res. 2012; 43 (4): 283-289. doi: 10.1016/j.jsr.2012.08.009 23127678
4. Ruhm CJ. Geographic variation in opioid and heroin involved drug poisoning mortality rates. Am J Prev Med. 2017; 53 (6): 745-753. doi: 10.1016/j.amepre.2017.06.009 28797652
5. US Department of Health and Human Services. 5-Point strategy to combat the opioid crisis. https://www.hhs.gov/opioids/about-the-epidemic/hhs-response/index.html. Accessed March 27, 2019.
6. Davis C, Carr D. State legal innovations to encourage naloxone dispensing. J Am Pharm Assoc (2003). 2017; 57 (2S): S180-S184. doi: 10.1016/j.japh.2016.11.007 28073688
7. Wheeler E, Jones TS, Gilbert MK, Davidson PJ; Centers for Disease Control and Prevention (CDC). Opioid overdose prevention programs providing naloxone to laypersons-United States, 2014. MMWR Morb Mortal Wkly Rep. 2015; 64 (23): 631-635. 26086633
8. Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014; 8 (3): 153-163. doi: 10.1097/ADM.0000000000000034 24874759
9. Bazazi AR, Zaller ND, Fu JJ, Rich JD. Preventing opiate overdose deaths: examining objections to take-home naloxone. J Health Care Poor Underserved. 2010; 21 (4): 1108-1113. 21099064
10. Kim D, Irwin KS, Khoshnood K. Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality. Am J Public Health. 2009; 99 (3): 402-407. doi: 10.2105/AJPH.2008.136937 19150908
11. Doleac JL, Mukherjee A. The moral hazard of lifesaving innovations: naloxone access, opioid abuse, and crime. https://ssrn.com/abstract=3135264. Published September 30, 2018. Accessed March 27, 2019.
12. Rees DI, Sabia JJ, Argys LM, Latshaw J, Dave D. With a little help from my friends: the effects of naloxone access and Good Samaritan laws on opioid-related deaths (No. w23171). New York, NY: National Bureau of Economic Research; 2017. doi: 10.3386/w23171
13. McClellan C, Lambdin BH, Ali MM, Opioid-overdose laws association with opioid use and overdose mortality. Addict Behav. 2018; 86: 90-95. doi: 10.1016/j.addbeh.2018.03.014 29610001
14. Pardo B. Do more robust prescription drug monitoring programs reduce prescription opioid overdose? Addiction. 2017; 112 (10): 1773-1783. doi: 10.1111/add.13741 28009931
15. Henry J Kaiser Family Foundation. 2018. Medicaid's Role in Addressing the Opioid Epidemic. https://www.kff.org/infographic/medicaids-role-in-addressing-opioid-epidemic/. Published February 27, 2018. Accessed March 27, 2019.
16. Roberts AW, Carpenter DM, Smith A, Look KA. Reviewing state-mandated training requirements for naloxone-dispensing pharmacists. Res Social Adm Pharm. 2019; 15 (2): 222-225. 29650444
17. The South Carolina Board of Medical Examiners and the South Carolina Board of Pharmacy's joint protocol to initiate dispensing of naloxone HCl without a prescription. https://www.llr.sc.gov/pol/pharmacy/PFORMS/Joint-Naloxone-Protocol.pdf. Published November 17, 2016. Accessed March 27, 2019.
18. Meriwether S. Order certifying the changes to regulations of the Board of Pharmacy. https://aws.state.ak.us/OnlinePublicNotices/Notices/Attachment.aspx?id=105525. Published January 22, 2017. Accessed March 27, 2019.
19. Buchmueller TC, Carey C. The Effect of prescription drug monitoring programs on opioid utilization in Medicare. Am Econ J Econ Policy. 2018. doi: 10.1257/pol.20160094
20. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med. 2014; 174 (10): 1668-1673. doi: 10.1001/jamainternmed.2014.4005 25154332
21. Powell D, Pacula RL, Jacobson M. Do medical marijuana laws reduce addictions and deaths related to pain killers? J Health Econ. 2018; 58: 29-42. doi: 10.1016/j.jhealeco.2017.12.007 29408153
22. Bradford AC, Bradford WD, Abraham A, Bagwell Adams G. Association between US state medical cannabis laws and opioid prescribing in the Medicare Part D population. JAMA Intern Med. 2018; 178 (5): 667-672. doi: 10.1001/jamainternmed.2018.0266 29610897
23. Dimick JB, Ryan AM. Methods for evaluating changes in health care policy: the difference-in-differences approach. JAMA. 2014; 312 (22): 2401-2402. doi: 10.1001/jama.2014.16153 25490331
24. Frank RG, Humphreys K, Pollack HA. Does naloxone availability increase opioid abuse? the case for skepticism. Health Affairs Blog. https://www.healthaffairs.org/do/10.1377/hblog20180316.599095/full/. Published March 19, 2018. Accessed March 27, 2019.
25. Davis CS, Carr D. Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend. 2015; 157: 112-120. doi: 10.1016/j.drugalcdep.2015.10.013 26507172
26. Gupta R, Shah ND, Ross JS. The rising price of naloxone-risks to efforts to stem overdose deaths. N Engl J Med. 2016; 375 (23): 2213-2215. doi: 10.1056/NEJMp1609578 27959694
27. Ruhm CJ. Drug poisoning deaths in the United States, 1999-2012: a statistical adjustment analysis. Popul Health Metr. 2016; 14 (1): 2. doi: 10.1186/s12963-016-0071-7 26778921
28. Hollingsworth A, Ruhm CJ, Simon K. Macroeconomic conditions and opioid abuse. J Health Econ. 2017; 56: 222-233. doi: 10.1016/j.jhealeco.2017.07.009 29128677